indication

Psychoses

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
4
2 approved · 2 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
46 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 21 trial
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Sarcosine
Pipeline · Phase 2
Phase 23 trials
OwnerChina Medical University Hospital
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 41 trial
OwnerShanghai Mental Health Center
Protection2038

Market size

prevalence as a range, not a number